Important Safety Information | NIOX VERO® User Manual (PDF)

For US Healthcare Professionals Only

For questions about coronavirus/COVID-19 and using NIOX VERO®, please visit the NIOX VERO Coronavirus/COVID-19 FAQ.

Publications & Whitepapers

Noteworthy Publications

Clinical Studies

Anderson WJ, Short PM, Jabbal S, et al. Inhaled corticosteroid dose response in asthma. Should we measure inflammation? Ann Allergy Asthma Immunol. 2017; 118: 179-185.

Coumou H, Westerhof GA, de Nijs SB, et al. Predictors of accelerated decline in lung function in adult-onset asthma. Eur Respir J. 2018; 51: 1701785.

Hanania N, Massanari M, Jain N. Measurement of fractional exhaled nitric oxide in real-world clinical practice alters asthma treatment decisions. Ann Allergy Asthma Immunol. 2018; 120: 414–418.

Karrasch S, Linde K, Rücker G, et al. Accuracy of FENO for diagnosing asthma: a systematic review. Thorax. 2017; 72: 109–116.

Morten M, Collison A, Murphy VE, et al. Managing Asthma in Pregnancy (MAP) trial: FeNO levels and childhood asthma. J Allergy Clin Immunol. 2018; 142: 1765-1772.

Price D, Buhl R, Chan A, et al. Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial. Lancet Respir Med. 2017; 6: 29-39.

Cost Effectiveness

Arnold RJ, Massanari M, Lee TA, Brooks E. A Review of the Utility and Cost Effectiveness of Monitoring Fractional Exhaled Nitric Oxide (FeNO) in Asthma Management. Manag Care. 2018; 27(7): 34-41.

Arnold RJG, Layton A, Massanari M. Cost impact of monitoring exhaled nitric oxide in asthma management. Allergy Asthma Proc. 2018; 39(5): 338-344.

Brooks EA, Massanari M. Cost-Effectiveness Analysis of Monitoring Fractional Exhaled Nitric Oxide (FeNO) in the Management of Asthma. Manag Care. 2018; 27(7): 42-48.

Evidence Reviews

Petsky HL, Cates CJ, Kew KM, et al. Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): a systematic review and meta-analysis. Thorax. 2018; 73(12): 1110-1119.

Pavord ID, Beasley R, Agusti A, et al. The Lancet Commissions. After Asthma: Refining Airways Diseases. Lancet. 2018; 391: 350-400.

Petsky HL, Kew KM, Turner C, et al. Exhaled nitric oxide levels to guide treatment for adults with asthma. Cochrane Database Syst Rev. 2016; 9: CD011440.

Petsky HL, Kew KM, Chang AB. Exhaled nitric oxide levels to guide treatment for children with asthma. Cochrane Database Syst Rev. 2016, 11: CD011439.

Wang Z, Pianosi P, Keogh K, et al. The Clinical Utility of Fractional Exhaled Nitric Oxide (FeNO) in Asthma Management. Comparative Effectiveness Review No. 197 (Prepared by the Mayo Clinic Evidence-based Practice Center under Contract No. 290-2015-00013-I). AHRQ Publication No.17(18)-EHC030-EF. Rockville, MD: Agency for Healthcare Research and Quality. December 2017. Accessed October 30, 2020.


GINA-Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). 2019. Full text available online at: Accessed on October 30, 2020.

NICE. National Institute for Health and Clinical Excellence. Asthma: diagnosis, monitoring and chronic asthma management NICE guideline [NG80]. November 2017. Available at: Accessed October 30, 2020.


Circassia White Paper. Evidence Supporting the Clinical Value of Measuring Exhaled Nitric Oxide (FeNO) in the Diagnosis and Management of Asthma. Circassia Pharmaceuticals, Inc. September 2019.